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Abstract: Objective and design Interleukin-13 (IL-13) has recently been reported to be a potential
cytokine in the pathogenesis of minimal-change nephrotic syndrome (MCNS).
However, the mechanistic insights associated with podocyte dysfunction mediated by
IL-13-induced changes in various slit diaphragm (SD) and cytoskeletal molecules have
not yet been shown in cultured human podocytes in vitro yet.
Materials Human conditionally immortalized podocytes were used
Treatment Podocytes were incubated with various concentrations of IL-13 during the
indicated time periods (6, 12, and 24 h) and montelukast was administered with the
dose of 0.1 μg.
Results Treatment of IL-13 resulted in a progressive decrease in distinct processes or
projections of the human podocytes and high dose of IL-13 increased podocyte
permeability in vitro at 6 hours. IL-13 had a substantial impact on the redistribution and
rearrangement of zonula occludens (ZO)-1, synaptopodin, α-actinin, CD2-associated
protein (CD2AP) in podocytes and disrupted the cytoskeletal connections in a
concentration-dependent manner on confocal microscopy. IL-13 also down-modulated
ZO-1, synaptopodin, α-actinin, CD2AP and p130Cas at protein levels and up-regulated
β-catenin and B7-1 in podocytes. Furthermore, we demonstrated that down-modulated
changes in various SD and cytoskeletal structures of human podocytes induced by IL-
13 was significantly restored after treatment with montelukast with upregulation of B7-
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1.
Conclusion Our results suggest that targeting IL-13 may be one of the important
cytokines in the pathogenesis of MCNS and targeting IL-13 could be one of the
potential therapeutic strategies in MCNS.
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Abstract 
Objective and design Interleukin-13 (IL-13) has recently been reported to be a potential 
cytokine in the pathogenesis of minimal-change nephrotic syndrome (MCNS). However, the 
mechanistic insights associated with podocyte dysfunction mediated by IL-13-induced 
changes in various slit diaphragm (SD) and cytoskeletal molecules have not yet been shown 
in cultured human podocytes in vitro yet.  
Materials Human conditionally immortalized podocytes were used 
Treatment Podocytes were incubated with various concentrations of IL-13 during the 
indicated time periods (6, 12, and 24 h) and montelukast was administered with the dose of 
0.1 μg.  
Results Treatment of IL-13 resulted in a progressive decrease in distinct processes or 
projections of the human podocytes and high dose of IL-13 increased podocyte permeability 
in vitro at 6 hours. IL-13 had a substantial impact on the redistribution and rearrangement of 
zonula occludens (ZO)-1, synaptopodin, α-actinin, CD2-associated protein (CD2AP) in 
podocytes and disrupted the cytoskeletal connections in a concentration-dependent manner on 
confocal microscopy. IL-13 also down-modulated ZO-1, synaptopodin, α-actinin, CD2AP 
and p130Cas at protein levels and up-regulated β-catenin and B7-1 in podocytes. Furthermore, 
we demonstrated that down-modulated changes in various SD and cytoskeletal structures of 
human podocytes induced by IL-13 was significantly restored after treatment with 
montelukast with upregulation of B7-1.  
Conclusion Our results suggest that targeting IL-13 may be one of the important cytokines in 
the pathogenesis of MCNS and targeting IL-13 could be one of the potential therapeutic 
strategies in MCNS. 
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Key words: interleukin-13, slit diaphragm, cytoskeletal molecules, B7-1, podocytes, 
leukotriene receptor antagonists 
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Introduction 
Minimal-change nephrotic syndrome (MCNS) is the most common cause of nephrotic 
syndrome in children, but frequent relapses are often observed, requiring long-term use of 
corticosteroids [1]. However, the pathophysiologic mechanisms of MCNS are not fully 
understood and still elusive. Some studies have suggested that MCNS is a T helper (Th)2-
dominated disease, because higher levels of serum interleukin-13 (IL-13) were observed in 
patients with MCNS [2, 3] and overexpression of IL-13 led to podocyte injury and induced a 
minimal-change-like nephropathy in rats [4]. Currently, however, there has been scarce report 
on the effect of IL-13 on cultured human podocytes in vitro. Only our previous report showed 
that IL-13 could induce alterations in the content and localization of zonula occludens-1 (ZO-
1), one of the modified adherens junction (AJ) proteins [5].  
The podocyte is a highly differentiated cell with a unique cytoskeletal architecture, and 
forms the final glomerular filtration barrier by the formation and maintenance of foot 
processes (FPs) and the interposed slit diaphragms (SDs) [6-13]. The extracellular SD is 
linked to the intracellular actin-based cytoskeleton through adaptor proteins, such as CD2-
associated protein (CD2AP), zonula occludens (ZO)-1, β-catenin, and p130Cas, located at the 
intracellular SD insertion area near lipid rafts (6-13). Neighboring FPs are connected by a 
contractile apparatus consisting of F-actin, α-actinin-4 and synaptopodin [6-13]. 
Recently, CD80 expression on podocytes, also known as B7-1, has been proposed as a key 
player in the induction of proteinuria in MCNS [14-16]. However, the mechanistic insights 
associated with podocyte dysfunction mediated by IL-13-induced SD and cytoskeletal 
changes and upregulation of B7-1 have not yet been shown in vitro yet. The present study 
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shows that IL-13 down-modulates various SD and cytoskeletal structures at protein levels in 
human podocytes in vitro. Furthermore, we demonstrated that down-modulated changes in 
various adaptor proteins and cytoskeletal structures of human podocytes induced by IL-13 
was significantly restored after treatment with a leukotriene receptor antagonist (montelukast), 
which has been used to treat allergic diseases, in conjunction with the upregulation of B7-1, 
suggesting that targeting IL-13 in MCNS could be one of the potential therapeutic strategies 
by modulating B7-1. 
Materials and methods 
Cell culture of human podocytes 
Human conditionally immortalized podocytes (AB8/23), primarily cloned from human 
glomerular cultures, were characterized and generously provided by Dr. Moin A. Saleem 
(University of Bristol, Bristol, UK). Human podocytes were maintained in RPMI 1640 
(WelGENE, Daegu, Korea) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), Insulin-Transferrin-Selenium-Pyruvate Supplement (ITSP; WelGENE), and 
antibiotics. Fresh media was supplied once every two days.  
To stimulate human podocyte proliferation, cells were cultivated at 33℃ (permissive 
conditions) in a culture medium supplemented with human recombinant ITSP to induce 
expression of temperature-sensitive large T antigens. To induce differentiation, podocytes 
were maintained at 37℃ without ITPS (non-permissive conditions) for at least two weeks 
and for subculture, 0.05% trypsin was used to detach cells from the culture dishes [12]. 
 
IL-13 and montelukast treatment conditions 
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To imitate MCNS-like conditions, cells were incubated with various concentrations of IL-13 
(Peprotech Inc., Rocky Hill, NJ, USA) during the indicated time periods (6, 12, and 24 h). IL-
13 was administered with 1, 3, 5, 10, 20, 30, and 100 μg doses, respectively, into 0.5% RPMI 
at 37℃. Montelukast (Sigma-Aldrich Inc., St. Louis, MO, USA) was administered with the 
dose of 0.1 μg.  
 
Monolayer permeability assay 
Podocytes were seeded and grown to confluence in a monolayer pattern on the surface of 
0.45 μm cellulose semi-permeable membranes (Millicell-HA, Millipore Corp., Bedford, MA, 
USA) in 10% RPMI. Hydrostatic pressure was applied continuously from lower to apical to 
basolateral aspect. Treated Cells were incubated with various concentrations of IL-13 during 
the indicated 24-h period in 0.5% RPMI. Then, 1 mg/mL FITC-tagged anionic dextran 
(Invitrogen, Eugene, OR, USA) was added to the apical media, and the filtered amounts of 
dextran at each incubation time (2, 4, 6, 8, 16, and 24 h) were measured by 
spectrophotometry at 492 nm. 
 
Scanning Electron Microscopy  
A Hitachi S-570 scanning electron microscopy (SEM; Hitachi, Tokyo, Japan) was used to 
view samples for SEM. The collagen-coated and differentiated cells were fixed in 5% 
glutaraldehyde in distilled water, incubated at 4°C for 1 h, rinsed three times in phosphate 
buffered saline (PBS), and then dehydrated in a graded series of ethanol solutions (60%, 70%, 
80%, 95%, and 100% ethanol) for 7 min in each solution. The same process was performed 
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once more with the exception of fixation in 1% osmium tetroxide in distilled water. The cells 
were dried before coating with gold and observed by a SEM. 
 
Immunoﬂuorescence staining and confocal image analysis 
Human podocytes that were grown on type I collagen-coated glass cover slips were incubated 
at 37°C for 2 h and fixed in 4% paraformaldehyde for 20 min. The cells were then 
permeabilized in 0.1% tritonX-100 for 10 min, blocked with 10% FBS for 30 min, washed 
three times for 5 min in phosphate buffered saline (PBS), and labeled with monoclonal rabbit 
anti-ZO-1 antibody (Invitrogen, Eugene, OR, USA), polyclonal goat anti-rat synaptopodin 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). polyclonal goat antimouse α-actinin 
antibody (Santa Cruz Biotechnology), polyclonal rabbit anti-rat CD2AP antibody (Santa Cruz 
Biotechnology). Primary antibody-bound specimens were incubated with 1:1000 (v/v) Alexa 
594 for red conjugates and Alexa 488 for green (Invitrogen), respective of secondary anti-
rabbit IgG, at room temperature for 40 min and at 37°C for 20 min without CO2. Nuclei were 
stained with 4’-6-diamidino-2-phenylindole (DAPI) (1:1000) for 20 min in PBS. A mounting 
medium is used to adhere coverslips to the slide and viewed with a fluorescence microscope 
(Leica TCS SP2 AOBS, Mannheim, Germany). The densitometry values of the fluorescent 
bands were analyzed using the Image J image processing and analysis software (National 
Institutes of Health, Bethesda, MD, USA). 
 
Western blotting 
Confluent cell layers were incubated with additives for various time durations, and proteins 
were extracted using a protein extraction solution PRO-PREP (Intron Biotechnology, 
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Seongnam, Gyeonggi, South Korea) containing phenylmethylsulfonyl fluoride, 
ethylenediamine tetraacetic acid, pepstatin A, leupeptin, and aprotinin; protein concentrations 
were then determined. To perform western blotting for ZO-1, synaptopodin, α-actinin, 
CD2AP, β-catenin, p130Cas and B7-1, 30 μg of boiled extracts were resolved on 10% SDS-
PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corp., 
Medford, MA, USA). 
The membranes were then washed with methanol and blocked in 5% fat-free milk before 
incubation with monoclonal rabbit anti-ZO-1 antibody (Invitrogen), polyclonal goat anti-rat 
synaptopodin (Santa Cruz Biotechnology). polyclonal goat anti-mouse α-actinin antibody 
(Santa Cruz Biotechnology), polyclonal rabbit anti-rat CD2AP antibody (Santa Cruz 
Biotechnology), polyclonal rabbit anti-rat p130Cas antibody (Santa Cruz Biotechnology), 
polyclonal rabbit anti-rat β-catenin (Santa Cruz Biotechnology) or anti-B7-1 antibody (Santa 
Cruz Biotechnology). Anti-β-tubulin antibody (Santa Cruz Biotechnology) was used as a 
loading control. After incubation with horseradish peroxidase-conjugated secondary 
antibodies (Santa Cruz Biotechnology), protein bands were detected using the enhanced 
chemiluminescence (ECL) detection system (WEST-ZOL® plus; Amersham Biotech Ltd., 
Bucks, UK). Density values are expressed as percentages of the control. Data on 
densitometric analysis of the respective proteins/β-tubulin ratio were expressed as mean ± 
standard deviation (SD). 
 
Statistical analysis 
Results were described as the mean ± SD, as appropriate under different conditions. The 
significance of the data was assessed using Student t-test and nonparametric Kruskal-Wallis 
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statistical analysis using SPSS version 20.0 (SPSS Inc, Chicago, IL, U.S.A.). P values < 0.05 
are considered significant. In the Figure, statistical significance is indicated by asterisks (*). 
*P < 0.05; **P < 0.01.  
 
Results 
Ultrastructural changes in human podocytes by IL-13  
Human podocytes were treated with PAN and a high dose of IL-13 to induce an experimental 
nephrotic syndrome. Under scanning electron microscopy (SEM), there seemed to be 
podocytes with dense and tufted structures in the differentiated condition, but the cells 
displayed fewer distinct processes or projections in puromycin aminonucleoside (PAN)-
induced podocyte injury (Supplementary Figure S1 online). As in PAN-induced podocyte 
injury, SEM ultrastructural analyses also revealed a progressive decrease in distinct processes 
or projections of the human podocytes after treatment with IL-13, particularly documented at 
100 ng/mL of IL-13 (Supplementary Figure S1 online).  
 
Changes in podocyte permeability by IL-13 
High concentration (100 ng/mL) of IL-13 increased podocyte permeability in vitro to peak 
levels greater than 250% compared to the control (without IL-13) at 6 h, and then levels 
decreased to be similar to low concentrations of IL-13 by 8 hr (Supplementary Figure S2 
online). IL-13 of the doses ≥ 3 ng/mL gradually increased the overall permeability by 24 h. 
These findings show that high dose of IL-13 mainly increases podocyte permeability at early 
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stages (2-6 h), suggesting the functional explanation of the cytoskeletal changes shown by 
confocal microscopy after IL-13 incubation. After 6 hours, the permeability continued to 
increase, possibly due to senescence of the podocytes.  
 
Distribution of SD and cytoskeletal molecules of podocytes on confocal microscopy 
Podocytes were double-stained for ZO-1 and synaptopodin and the cell nuclei were stained 
with 4′,6-diamidino-2-phenylindole (DAPI). ZO-1 in human podocytes was highly expressed 
within the podocyte in the cytoplasmic aspect of the FP membrane, adjacent to the insertion 
of the SD, and synaptopodin is an actin-associated protein that may play a role in actin-based 
cell shape and motility (Fig. 1) [6, 7]. ZO-1 was distributed to the cell contact areas under 
physiologic conditions without IL-13 but was redistributed and internalized into the inner 
cytoplasm from the peripheral cell membrane as IL-13 concentrations increased (Fig. 1). 
Distribution of synaptopodin became more fused and conglomerated as IL-13 concentrations 
increased (Fig. 1).  
α-Actinin-4 is located in the center of foot process and interacts with integrins and 
strengthens the podocyte-glomerular basement membrane (GBM) interaction and CD2AP is 
expressed primarily in podocytes at the cytoplasmic face of the SD and lipid rafts and serves 
as an adaptor anchoring nephrin and podocin to actin filaments of podocyte cytoskeleton [6, 
7]. α-actinin and CD2AP were distributed to the cell surface areas under physiologic 
conditions without IL-13 but was redistributed and internalized into the cytoplasm and 
perinuclear areas from the cell surface areas as IL-13 concentrations increased (Fig. 2). These 
results suggest that IL-13 may have a substantial impact on the redistribution and 
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rearrangement of SD and cytoskeletal molecules in human podocytes and disrupts the 
cytoskeletal connections in a concentration-dependent manner. 
 
Protein assays for adaptor and cytoskeletal molecules of podocytes by western blotting 
In human podocytes, density values for ZO-1 (69 kD), synaptopodin (100 kD) and α-actinin 
(100 kD) proteins tended to decrease with IL-13 treatment in a dose-dependent manner at 12 
h (Fig. 3). A dose of 20 ng/mL IL-13 significantly decreased the amount of ZO-1, 
synaptopodin and α-actinin protein in human podocytes at 12 h (P < 0.05) (Fig. 3). A dose of 
≥ 10 ng/mL IL-13 significantly decreased the amount of CD2AP protein in human podocytes 
at 6 h (P < 0.01). The reduced CD2AP protein levels (90 kD) by 30 and 100 ng/mL IL-13 was 
restored by 0.1 μM montelukast (P < 0.05) (Fig. 4). A dose of ≥ 3 ng/mL IL-13 significantly 
increased the amount of β-catenin protein (90 kD) in human podocytes at 12 h (P < 0.05). 
The increased β-catenin protein levels by 30 and 100 ng/mL IL-13 was slightly decreased by 
0.1 μM montelukast, although it was not statistically significant (Fig. 5). A dose of ≥ 3 ng/mL 
IL-13 significantly decreased the amount of p130Cas protein (130 kD) in human podocytes at 
6 and 12 h (P < 0.01). The reduced p130Cas protein levels by 30 and 100 ng/mL IL-13 was 
significantly increased by 0.1 μM montelukast (P < 0.01) (Fig. 6). A dose of 10 and 30 ng/mL 
IL-13 significantly increased the amount of B7-1 protein (60 kD) in human podocytes at 6 
and 12 h (P < 0.05). The increased B7-1 protein levels by 30 ng/mL IL-13 was significantly 
decreased by 0.1 μM montelukast (P < 0.05) (Fig. 7).  
 
Discussion    
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The pathogenic mechanisms of proteinuria in MCNS have not been elucidated. Since 
Shalhoub proposed the hypothesis of MCNS is a disorder of T-cell dysfunction [17], several 
cytokines, such as IL-1, 2, 8, 12 and interferon-gamma, have been suggested to be involved 
in the pathogenesis of MCNS [18]. However, the results have not been consistent in 
subsequent studies [18]. Among various cytokines, IL-13 has recently been reported to be 
increased during relapse of MCNS [2, 3]. In addition, IL-13-transfected rats, showed about 
80% effacement of podocyte foot processes on electron microscopy in association with the 
downregulation of nephrin, podocin and dystroglycan [4]. Although our preliminary study 
have shown that IL-13 could induce the alterations in the content and localization of ZO-1 in 
human podocytes [5], there has been no comprehensive study to test whether IL-13 could 
affect the other various adaptor proteins and cytoskeletal changes in cultured human 
podocytes in vitro and their potential mechanisms, which would be important to understand 
the pathogenesis of MCNS.  
 Our study firstly demonstrated that IL-13-treated cultured human podocytes showed a 
progressive decrease in distinct processes or projections similar to the PAN-induced podocyte 
changes, which is considered to be a traditional model of MCNS, on SEM analysis. Although 
PAN-induced podocyte injury is mediated by oxidative stress and direct insults [19, 20], we 
thought that the pathogenic mechanisms of IL-13-induced podocyte changes might be 
different from PAN-induced changes, because the pathogenesis of human MCNS might not 
be related to chemical podocyte injury, considering that there are no histological changes in 
glomeruli of MCNS. 
We also showed that IL-13 increased podocyte permeability in addition to changes in 
morphology of processes of cultured human podocytes as in our previous studies such as 
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glucose- or PAN-induced podocytes [20-22]. Although the precise mechanisms of these 
deleterious effects have not been fully understood, derangement of the various SD and actin 
cytoskeleton molecules has been proposed as the common pathway leading to foot process 
effacement in podocytes [6, 13]. In the present study, we newly demonstrated that IL-13 had 
a substantial impact on the redistribution and rearrangement of ZO-1, synaptopodin, α-actinin, 
CD2AP in podocytes and disrupted the cytoskeletal connections in a concentration-dependent 
manner on confocal microscopy. IL-13 also down-modulated ZO-1, synaptopodin, α-actinin, 
CD2AP and p130Cas and up-regulated β-catenin at protein levels in cultured human 
podocytes. A well-developed SD, adaptor proteins, and actin cytoskeletal structures play an 
important role in the maintenance of podocyte foot processes architecture and filtration 
barrier function [6-13]. ZO-1, synaptopodin, α-actinin, CD2AP and p130Cas are all important 
SD-binding adaptor proteins or actin cytoskeletal molecules for maintaining podocyte 
integrity, and disruption of these molecules can cause podocyte permeability as shown in our 
previous and current studies [5, 20-26]. Recently, β-catenin has been shown to be involved in 
many pathological processes in podocytes [27]. Emerging evidence suggests that β-catenin is 
activated in podocytes in various proteinuric kidney diseases and genetic or pharmacologic 
activation of β-catenin is sufficient to impair podocyte integrity and causes proteinuria in 
healthy mice. Conversely, podocyte-specific ablation of β-catenin protects against proteinuria 
after kidney injury [27-29]. Our results also showed that IL-13 increased β-catenin levels in 
cultured human podocytes. 
Recently, upregulation of B7-1 has been regarded to be one of the mechanisms involved in 
the development of MCNS [13-16]. This concept was firstly suggested by Reiser et al. in 
which lipopolysaccharide (LPS) was capable of up-regulation of B7-1, leading to nephrotic-
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range proteinuria and reorganization of vital slit diaphragm proteins [30]. Conversely, 
proteinuria was not seen in LPS-treated B7-1 knockout mice, suggesting a pivotal role for 
this molecule in the development of proteinuria [30]. Ishimoto et al. also showed that sera 
from MCD in relapse, but not in remission, significantly increased B7-1 expression (P < 
0.004) and B7-1 protein secretion by podocytes [16]. In addition, increased B7-1 urinary 
excretion was elevated in MCNS patients [14]. Also, overexpression of IL-13 caused 
upregulation of B7-1 in IL-13-transfected rats [4], but there has been no study to test whether 
IL-13 could increase B7-1 molecule in cultured human podocytes in vitro. Our study firstly 
showed that B7-1 was upregulated after IL-13 treatment in podocytes, which could be related 
to the disruption of the various SD and cytoskeletal changes in podocytes. However, the 
values of B7-1 expression is currently highly debated, since many working groups could not 
repeat the initially findings. Fiorina et al. showed that the immune-related molecule B7-
1/CD80 is a critical mediator of podocyte injury in type 2 diabetic nephropathy (31), but 
Baye et al. demonstrated that the costimulatory receptor B7-1 was not induced in injured 
podocytes in several mouse models of podocyte injury including treatment with 
lipopolysaccharide or Adriamycin, a lupus prone model (NZB/W F1) and subtotal 
nephrectomy (32).  
To test the hypothesis that targeting IL-13 with a leukotriene receptor antagonist which is 
widely used in the treatment of many allergic diseases [33] could be beneficial in IL-13-
stimulated cultured human podocytes, we treated montelukast in IL-13-stimulated podocytes. 
Leukotriene metabolism in podocytes has not been reported previously. In experimental 
models of allergic diseases, it was well known that montelukast exerts its anti-inflammatory 
effect through the suppression of T helper type-2 (Th2) cytokines such as IL-4, IL-5 and IL-
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13 [34]. We demonstrated that changes in various SD-binding adaptor proteins and 
cytoskeletal structures of human podocytes induced by IL-13 were significantly restored after 
the treatment with montelukast in conjunction with the upregulation of B7-1. In podocyte 
levels, we speculate that upregulation of cysteinyl leukotriene 1 receptor by IL-13 which is 
might be blocked by montelukast. 
However, our study has some limitations. Firstly, it remains unclear whether the applied 
concentrations of IL-13 and montelukast reflect the serum concentrations in the animal model 
or in patients. Secondly, the dose of IL-13 used in in vitro study cannot be applied to the 
patients due to different conditions. Nevertheless, we firstly demonstrated that IL-13 could 
induce a progressive decrease in distinct processes or projections of the cultured human 
podocytes, which could be used as a new in vitro model of MCNS in addition to previous 
PAN and LPS-induced models. IL-13 also resulted in increased podocyte permeability, the 
redistribution and rearrangement or changes in protein contents of various SD-binding 
adaptor proteins and cytoskeletal molecules in conjunction with the upregulation of B7-1. 
Restoration of these changes in the cultured human podocytes after montelukast treatment 
suggests that IL-13 could have a direct impact on the cultured human podocytes, responsible 
for the development of proteinuria in MCNS. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
Acknowledgement 
The part of this article was presented as a poster presentation in the 16th IPNA congress in 
2013, Shanghai, China (Interleukin-13 may increase podocyte permeability via modulation of 
zonula occludens-1). The authors would like to thank Keum Hwa Lee for her arranging 
references and proof‐reading.  
Author contributions  
T. S. Ha, J. A. Nam, S. B. Seong, M.A. Saleem, S. J. Park and J. I. Shin designed study, 
coordinated data acquisition, statistically analyzed and interpreted the data, drafted and 
revised the manuscript. All authors read and approved the final manuscript.  
Competing Financial Interests: This research was supported by the Basic Science Research 
Program through the National Research Foundation of Korea (NRF) and funded by the 
Ministry of Education, Science and Technology (2011-0013789, 2013R1A1A1012112 and 
2015R1C1A1A01052984) to J.I. Shin and partly supported by Basic Science Research 
Program through the National Research Foundation of Korea (NRF) funded by the Ministry 
of Education (NRF-2013R1A1A4A03006207) to T.S. Ha. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
17 
 
References    
 
1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362:629-39.  
2. Cheung W, Wei CL, Seah CC, Jordan SC, Yap HK. Atopy, serum IgE, and interleukin-
13 in steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2004;19:627-32.  
3. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC. Th1 and Th2 
cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased 
IL-13 mRNA expression in relapse. J Am Soc Nephrol. 1999;10:529-37.  
4. Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, et al. Overexpression of 
interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol. 
2007;18:1476-85. 
5. Park SJ, Saleem MA, Nam JA, Ha TS, Shin JI. Effects of interleukin-13 and 
montelukast on the expression of zonula occludens-1 in human podocytes. Yonsei 
Med J. 2015;56:426-32. 
6. Welsh GI, Saleem MA. The podocyte cytoskeleton--key to a functioning glomerulus 
in health and disease. Nat Rev Nephrol. 2011;8:14-21. 
7. Ha TS. Roles of adaptor proteins in podocyte biology. World J Nephrol. 2013;2:1-10. 
8. Greka A, Mundel P. Cell biology and pathology of podocytes. Annu Rev Physiol. 
2012;74:299-323. 
9. Reiser J, Kriz W, Kretzler M, Mundel P. The glomerular slit diaphragm is a modified 
adherens junction. J Am Soc Nephrol. 2000;11:1-8. 
10. George B, Holzman LB. Signaling from the podocyte intercellular junction to the 
actin cytoskeleton. Semin Nephrol. 2012;32:307-18.  
11. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of 
podocyte structure and function by components of the actin cytoskeleton. Trends Cell 
Biol. 2007;17:428–37. 
12. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, et al. A 
conditionally immortalized human podocyte cell line demonstrating nephrin and 
podocin expression. J Am Soc Nephrol. 2002;13:630-8. 
13. Ding WY, Saleem MA. Current concepts of the podocyte in nephrotic syndrome. 
Kidney Res Clin Pract. 2012;31:87-93.  
14. Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, et al. Urinary CD80 
is elevated in minimal change disease but not in focal segmental glomerulosclerosis. 
Kidney Int. 2010;78:296-302. 
15. Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, et al. Urinary CD80 
excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol. 2009; 
20:260-6.  
16. Ishimoto T, Cara-Fuentes G, Wang H, Shimada M, Wasserfall CH, Winter WE, et al. 
Serum from minimal change patients in relapse increases CD80 expression in 
cultured podocytes. Pediatr Nephrol. 2013;28:1803-1812. 
17. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 
1974;2:556-60. 
18. Zhang Sy, Audard V, Fan Q, Pawlak A, Lang P, Sahali D. Immunopathogenesis of 
idiopathic nephrotic syndrome. Contrib Nephrol. 2011;169:94-106. 
19. Gwinner W, Landmesser U, Brandes RP, Kubat B, Plasger J, Eberhard O, et al. 
Reactive oxygen species and antioxidant defense in puromycin aminonucleoside 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
glomerulopathy. J Am Soc Nephrol. 1997;8:1722–31. 
20. Ha TS, Park HY, Seong SB, Ahn HY. Puromycin aminonucleoside increases podocyte 
permeability by modulating ZO-1 in an oxidative stress-dependent manner. Exp Cell 
Res. 2016;340:139-49. 
21. Ha TS. High-glucose and advanced glycosylation end products increased podocyte 
permeability via PI3-K/Akt signaling. J Mol Med (Berl). 2010;88:391-400. 
22. Ha TS, Choi JY, Park HY, Lee JS. Ginseng total saponin improves podocyte 
hyperpermeability induced by high glucose and advanced glycosylation endproducts. 
J Korean Med Sci. 2011;26:1316-21. 
23. Ha TS, Choi JY, Park HY, Nam JA, Seong SB. Ginseng total saponin modulates the 
changes of α-actinin-4 in podocytes induced by diabetic conditions. J Ginseng Res. 
2014;38:233-8. 
24. Ha TS, Hong EJ, Han GD. Diabetic conditions downregulate the expression of 
CD2AP in podocytes via PI3-K/Akt signalling. Diabetes Metab Res Rev. 2015;31:50-
60. 
25. Ha TS, Choi JY, Park HY, Han GD. Changes of podocyte p130Cas in diabetic 
conditions. J Nephrol. 2013;26:870-6. 
26. Ha TS, Choi JY, Park HY. Puromycin aminonucleoside modulates p130Cas of 
podocytes. Korean J Pediatr. 2012;55:371-6. 
27. Zhou L, Liu Y. Wnt/β-catenin signalling and podocyte dysfunction in proteinuric 
kidney disease. Nat Rev Nephrol. 2015;11:535-45. 
28. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin 
signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol. 
2009;20:1997-2008. 
29. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/β-catenin signaling by paricalcitol 
ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22:90-103. 
30. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, et al. Induction of 
B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 
2004;113:1390-7. 
31. Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, et al. Role 
of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol. 2014;25:1415-29. 
32. Baye E, Gallazzini M, Delville M, Legendre C, Terzi F, Canaud G. The 
costimulatory receptor B7-1 is not induced in injured podocytes. Kidney Int. 
2016;90:1037-44. 
33. Leonardi S, Marchese G, Marseglia GL, La Rosa M. Montelukast in allergic diseases 
beyond asthma. Allergy Asthma Proc. 2007;28:287-91. 
34. Wu AY, , Chik SC, Chan AW, Li Z, Tsang KW, Li W. Anti-inflammatory effects of 
high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy. 
2003;33:359-66.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
19 
 
Figure legends 
Fig. 1.  Distributional changes in ZO-1 and synaptopodin by IL-13 in cultured human 
podocytes. Magnification: 1,000 ⅹ; Scale bar = 20 μm. 
Fig. 2.  Distributional changes in α-actinin and CD2AP by IL-13 in cultured human 
podocytes. Magnification: 1,000 ⅹ; Scale bar = 20 μm. 
α-Actinin and CD2AP were redistributed and internalized into the cytoplasm and perinuclear 
areas from the cell surface areas as IL-13 concentrations increased (arrow heads) 
Fig. 3. Effects of IL-13 on ZO-1, synaptopodin and α-actinin protein levels in cultured 
human podocytes as assayed by Western blotting. 
Data on the densitometric analysis of the ZO-1, synaptopodin and α-actinin proteins/β-tubulin 
ratio are expressed as the mean ± SD. *P < 0.05. Blots have been run under the same 
experimental conditions and data were summarized from 3 separated experiments.  
Fig. 4. Effects of IL-13 with and without montelukast on CD2AP protein levels in 
cultured human podocytes as assayed by Western blotting. 
Data on the densitometric analysis of the CD2AP/β-tubulin ratio are expressed as the mean ± 
SD. *P < 0.05, **P < 0.01. Blots have been run under the same experimental conditions and 
data were summarized from 3 separated experiments.  
Fig. 5. Effects of IL-13 with and without montelukast on β-catenin protein levels in 
cultured human podocytes as assayed by Western blotting. 
Data on the densitometric analysis of the β-catenin/β-tubulin ratio are expressed as the mean 
± SD. *P < 0.05. Blots have been run under the same experimental conditions and data were 
summarized from 3 separated experiments.  
Fig. 6. Effects of IL-13 with and without montelukast on p130Cas protein levels in 
cultured human podocytes as assayed by Western blotting. 
Data on the densitometric analysis of the p130Cas/β-tubulin ratio are expressed as the mean ± 
SD. **P < 0.01. Blots have been run under the same experimental conditions and data were 
summarized from 3 separated experiments.  
Fig. 7. Effects of IL-13 with and without montelukast on B7-1 protein levels in cultured 
human podocytes as assayed by Western blotting. 
Data on the densitometric analysis of the B7-1/β-tubulin ratio are expressed as the mean ± SD. 
*P < 0.05, **P < 0.01. Blots have been run under the same experimental conditions and data 
were summarized from 3 separated experiments.  
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